Cantor Fitzgerald keeps Neutral rating for Amgen stock
AD HOC NEWS
Cantor Fitzgerald has reiterated a Neutral rating and a USD 400.00 price target for Amgen stock. This comes as Amgen announced positive Phase 3 trial results for dazodalibep and reported strong second-quarter earnings that surpassed analyst expectations. Despite these positive developments, the stock is trading below its yearly high, with analyst targets varying significantly.
Read the full story
This is a short summary. The complete article is published by AD HOC NEWS.
Headline and summary aggregated from public news feeds. For information only — not financial advice.